share_log

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $54

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $54

HC Wainwright & Co.维持对UroGen Pharma的买入,将目标股价提高至54美元
Benzinga ·  2023/08/01 06:21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $23 to $54.

HC Wainwright & Co. 分析师Raghuram Selvaraju维持UroGen Pharma(纳斯达克股票代码:URGN)的买入,并将目标股价从23美元上调至54美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发